

**FDA Staff Manual Guides, Volume I – Organizations and Functions**

**Department of Health and Human Services**

**Food and Drug Administration**

**Center for Drugs Evaluation and Research**

**Office of Generic Drugs**

**Office of Bioequivalence**

**Division of Clinical Review**

Effective Date: December 14, 2018


**1. Division of Clinical Review (DCDMBD).**

- A. Evaluates bioequivalence studies with clinical endpoints and protocols supporting Abbreviated New Drug Applications (ANDAs) and supplements to ANDAs.
- B. Recommends approval, disapproval, or new bioequivalence with clinical endpoints and/or protocols.
- C. Identifies potential clinical safety or product use issues or bioequivalence problems and provides guidance for resolving the matters.
- D. Reviews and evaluates drug disposition data and specialized drug delivery systems to assure bioequivalence of generic drug products.

**2. Authority and Effective Date.**

The functional statements for the Division of Clinical Review were approved by the Secretary of Health and Human Services and effective on December 14, 2018.

**Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Bioequivalence  
Division of Clinical Review**



Staff Manual Guide 1292.14  
Organizations and Functions  
Effective Date: December 14, 2018

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Office of Bioequivalence, Division of Clinical Review organizational structures depicting all the organizational structures reporting to the Director:

Division of Clinical Review (DCDMBD)